financetom
Business
financetom
/
Business
/
Axsome Therapeutics' ADHD drug meets main goal in late-stage study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Axsome Therapeutics' ADHD drug meets main goal in late-stage study
Mar 25, 2025 4:35 AM

March 25 (Reuters) - Axsome Therapeutics ( AXSM ) said

on Tuesday its experimental drug to treat attention deficit

hyperactivity disorder (ADHD) met the main goal in a late-stage

study.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Carlyle Group Nears Advanced Talks to Acquire Majority Stake in Thyssenkrupp Unit
Market Chatter: Carlyle Group Nears Advanced Talks to Acquire Majority Stake in Thyssenkrupp Unit
Mar 18, 2024
08:17 AM EDT, 03/18/2024 (MT Newswires) -- Carlyle Group ( CG ) is close to entering advanced talks to acquire a majority stake of the naval shipbuilding unit of Thyssenkrupp, Bloomberg reported Monday, citing unnamed sources. The transaction could value the business at roughly 1.5 billion euros ($1.64 billion), Including debt, the report said. A Carlyle representative declined to comment,...
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation
Mar 18, 2024
08:26 AM EDT, 03/18/2024 (MT Newswires) -- Arch Biopartners Inc. ( ACHFF ), (ARCH.V) on Monday announced that it has published a peer reviewed paper in the British Medical Journal Open (BMJ Open) detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus. LSALT...
Market Chatter: Shift4 Payments' CEO Says Buyout Bids Failed to Value Firm Sufficiently
Market Chatter: Shift4 Payments' CEO Says Buyout Bids Failed to Value Firm Sufficiently
Mar 18, 2024
08:26 AM EDT, 03/18/2024 (MT Newswires) -- Shift4 Payments' ( FOUR ) Chief Executive Jared Isaacman said that potential acquirers have failed to sufficiently value the company with their bids, Bloomberg reported Sunday, citing an internal memo. According to the report, the company said in a Friday memo seen by Bloomberg that it has received multiple offers higher than its...
Nasdaq Investigates Connectivity Issues, Says All Systems Back to Normal
Nasdaq Investigates Connectivity Issues, Says All Systems Back to Normal
Mar 18, 2024
08:19 AM EDT, 03/18/2024 (MT Newswires) -- Nasdaq (NDAQ) said Monday it is investigating connectivity issues that impacted stock orders. The company said the issue was related to its matching engine, which matches and executes buy and sell orders in the exchange. Nasdaq reported the glitch at 4:55 a.m. ET and later said it had found the root cause. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved